Platelet-neutrophil interactions under thromboinflammatory conditions
Jing Li1, Kyungho Kim, Andrew Barazia
1Department of Pharmacology, University of Illinois College of Medicine, 835 S. Wolcott Ave, E403, Chicago, IL, 60612, USA.
Cellular and Molecular Life Sciences : CMLS
|February 5, 2015
Summary
Platelet-neutrophil interactions are crucial in vascular inflammation and thrombosis. Understanding how these cell communications are regulated is key to treating thromboinflammatory diseases.
Area of Science:
- Cardiovascular Biology
- Immunology
- Hematology
Background:
- Platelets are key in hemostasis and thrombosis, while leukocytes mediate immune responses.
- Platelet-leukocyte interactions at vascular injury sites link thrombosis and inflammation.
- Microvascular occlusion in thromboinflammation is significantly influenced by platelet-neutrophil interactions on activated endothelium.
Purpose of the Study:
- To review the regulatory mechanisms of platelet-neutrophil interactions.
- To elucidate the role of these interactions in thromboinflammatory diseases.
- To highlight current understanding and knowledge gaps in regulating these cellular communications.
Main Methods:
- Literature review of recent studies.
- Analysis of real-time imaging technologies.
- Examination of identified receptors and counter-receptors.
Main Results:
- Platelet-neutrophil interactions are critical determinants of microvascular occlusion.
- While major receptors are known, regulatory mechanisms under disease conditions are poorly understood.
- Thromboinflammation involves closely intertwined thrombosis and vascular inflammation.
Conclusions:
- Platelet-neutrophil interactions are central to thromboinflammatory disease pathogenesis.
- Further research is needed to understand the regulation of these interactions.
- Targeting these interactions may offer therapeutic strategies for thromboinflammatory conditions.
More Related Videos
Related Concept Videos
01:22Formation of the Platelet Plug
11.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
11.0K
01:38Inflammation
65.9K
Overview
65.9K
01:17Intracellular Signaling Affects Focal Adhesions
3.9K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.9K
01:16Clot Retraction and Fibrinolysis
10.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K